1 / 14

Diabetes Mellitus 101 for Medical Professionals

Diabetes Mellitus 101 for Medical Professionals. An Aggressive Pathophysiologic Approach to Cardiometabolic Therapy for Type 2 Diabetes :. Part 9. Stan Schwartz MD,FACP Clinical Associate Professor of Medicine, U of Pa. Cardiometabolic Institute Penn-Presbyterian Hospital, UPHS.

Patman
Télécharger la présentation

Diabetes Mellitus 101 for Medical Professionals

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Diabetes Mellitus 101 for Medical Professionals An Aggressive Pathophysiologic Approach to Cardiometabolic Therapy for Type 2 Diabetes: Part 9 Stan Schwartz MD,FACP Clinical Associate Professor of Medicine, U of Pa. Cardiometabolic Institute Penn-Presbyterian Hospital, UPHS

  2. Therapy for Type II Diabetes

  3. A1C (%) Normal: 4-6% Fasting/Preprandial (mg/dL)(plasma equivalent) Postprandial (mg/dL) (2-hour) ADA <7.0 90-130 <180* ACE <6.5 <110 <140 * Peak Targets for Glycemic Control Goals for individual patients may vary. Aim for the Lowest A1C Possible without Hypoglycemia. American Diabetes Association. Clinical Practice Recommendations. Diabetes Care. 2004,27:S15-S35 The American Association of Clinical Endocrinologists. Medical Guidelines for the Management of Diabetes Mellitus. Endocr Pract. 2002; 8(Suppl. 1): 40-82

  4. Relative Contribution of FBG and PPG Varies With A1C Range Inc PPG increases Micro- and macro- vascular disease Thus , to get to glycemic goals, one must control PPG as well as FBS. (incretins, alpha-glucosidase inhibitors, TZDs, glinides, fast-insulin analogues) Adapted from Monnier L, et al. Diabetes Care. 2003;26:881-885.

  5. Non-Insulin Therapy for Type II Diabetes

  6. Non-Insulin Therapy for Hyperglycemia in Type 2 Diabetes,Treating Defronzo’s Octet: Match Patient Characteristics to Drug Characteristics - - - Peripheral glucose uptake 1.Pancreatic insulin Secretion: Incretin, ranolazine 5.Gut CHO Absorption: Incretin, Pramlintide, Glucosidase inh. 7.Brain- TZD,INCRETIN, bromocryptine 2.Pancreatic glucagon Secretion- Incretin 8.Kidney- SGLT2 HYPERGLYCEMIA De 3.Muscle- TZD, Incretin Hepatic glucose production: Metformin, incretin 4.Liver 6.Fat- TZD, metformin

  7. Revised Treatment Algorithm At diagnosis: Lifestyle + metformin STEP 1 Tier 1* Tier 2† HbA1C >7.0% STEP 2 Add basal insulin Add sulfonylurea Add GLP-1 agonist Add pioglitazone ± SU Intensive insulin STEP 3 The New ADA Guidelines for Type 2 Diabetes:AKA- David Nathan’s Regimen- DNR NOT Glyburide, chlorpropamide NOT Rosiglitazone

  8. Simplified- AACE/ACE:Recommendations Based on A1C at Diagnosis Lifestyle Modifications Monotherapy Dual therapy Triple therapy A1C 6.5%-7.5% A1C 7.6%-9.0% A1C >9.0% If under treatment If drug naive Symptoms No symptoms Dual therapy Insulin plus other agent(s)* Insulin plus other agent(s)* Triple therapy Triple therapy *Pramlintide can be used with prandial insulin, but insulin secretagogues should be discontinued with multidose insulin Therapeutic Choice, based on Safety/ Efficacy, Should Match The Drug Characteristics With Patient Characteristics Rodbard HW, et al. Endocr Pract. 2009;15:540-559.

  9. Monotherapy Metformin Pioglitazone GLP-1 agonist Bromocriptine DPP-4 Inhibitor SGLT-2 Colsevelam AGI/Ranolazine Future AACE Guideline- Modest Proposal Asymptomatic 5.7 HbA1c Continuum 6.5%– if not at goal, advance Rx7.5% 9.0 12% Symptomatic Diet and Exercise • Insulin* • +/- Other agents • *Insulin analogs • Not NPH/regular •  If over 9.0% or above and symptomatic • If triple combo fails • Dual Combination • Metformin • Pioglitazone • GLP-1 agonist • Bromocriptine • DPP-4 Inhibitor • SGLT-2 • Colesevelam • AGI/Ranolazine • Triple Combination • Metformin • Pioglitazone • GLP-1 agonist • Bromocriptine • DPP-4 Inhibitor • SGLT-2 • Colesevelam • AGI/Ranolazine Prevention Pioglitazone [Incretin] [Bromocriptine] Metformin Colsevelam Therapeutic Choice Should Match The Drug Characteristics With Patient Characteristics

  10. Concurrent Therapy

  11. Aggressive medical therapy in diabetes ACE inhibitorsARBs β-blockersCCBsDiuretics Hypertension Atherosclerosis StatinsFibric acid derivatives Colsevalam Dyslipidemia MetforminTZDsSulfonylureas/GlinideRANOLAZINE colsevalam Incretins Insulin Hyperglycemia/ Insulin resistance ASAClopidogrelTiclopidine Platelet activationand aggregation Adapted from Beckman JA et al. JAMA. 2002;287:2570-81.

  12. Treating the ABCs Reduces Diabetic Complications 1 UKPDS Study Group (UKPDS 33). Lancet. 1998;352:837-853. 2 Hansson L, et al. Lancet. 1998;351:1755-1762. 3 UKPDS Study Group (UKPDS 38). BMJ. 1998;317:703-713. 4 Grover SA, et al. Circulation. 2000;102:722-727. 5 Pyŏrälä K, et al. Diabetes Care. 1997;20:614-620.

  13. Synergies In Therapy for the Cardiometabolic Syndrome ?√ ?√

  14. Summary Treat aggressively-benefit on cost and complications Treat elements of pathophysiology Resistance-glycemia,endothelial dysfunction,lipids,BP,coag. Secretion-first phase,incretin,importance of PPG Multi-hormonal issues Use SIDE-BENEFITS of the various agents Treat to new goals using combinations that make pathophysiologic sense Guidelines should help pick right drug(s) for right patients

More Related